Navigation Links
3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC

MENLO PARK, Calif., March 31, 2017 /PRNewswire/ -- 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and metabolic diseases, announced today that it will present data from its ongoing Phase 1 clinical study of TVB-2640 in solid tumor patients at the AACR annual meeting in Washington, D.C. The abstract "First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640" has been selected for an oral presentation as part of a mini-symposium session titled "Novel Agent and Intervention Clinical Trials" on April 4, 2017 at 4:05PM local time. The Principal Investigator presenting details about the trial is Dr. Gerald Falchook from the Sarah Cannon Research Institute at HealthONE, Denver, CO.

"As the first-in-human study now nears completion, we are very encouraged by the safety of, and preliminary activity seen with TVB-2640 in this group of highly pre-treated patients.  We are especially encouraged by the activity seen in KRAS mutant NSCLC, breast and ovarian cancers which will be described in more detail during the session at AACR", said Dr. Gerald Falchook. "We look forward to further development in Phase II studies, particularly given the poor prognosis and lack of effective therapies that target KRAS mutant NSCLC."

Presentation date: 4/4/2017

Presentation time: 4:05pm local time

Speaker: Dr. Gerald Falchook

About 3-V Biosciences

3-V Biosciences, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics in oncology and liver diseases based on expertise in lipid biology. The company's lead product candidate is a first-in-class inhibitor of fatty acid synthase (FASN) currently being evaluated in a Phase 1 clinical trial. Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. The company is located in Menlo Park, California.

Contact Information
Dennis Hom
Corporate Development & Finance
(650) 561-8600

To view the original version on PR Newswire, visit:

SOURCE 3-V Biosciences, Inc.
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
2. Neurocrine Biosciences to Present At The Deutsche Bank 38th Annual dbAccess Health Care Conference
3. Pressure BioSciences, Inc. to Present at the Marcum MicroCap Conference
4. Neurocrine Biosciences to Present at the Jefferies 2013 Global Healthcare Conference
5. Lilly Statement on Indiana Biosciences Research Institute
6. Pressure BioSciences Announces Core Technology Breakthrough
7. Alzheimers Drug Discovery Foundation Supports Madera Biosciences to Advance Small Molecule Drugs that Upregulate apoE
8. New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research
9. 3-V Biosciences Completes $20 Million Series C Financing
10. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
11. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
Post Your Comments:
(Date:5/27/2020)... (PRWEB) , ... May 27, 2020 , ... Focus ... and cloud solutions, has announced it will once again sponsor the American Heart Association’s ... Good Champion. This will mark the third year the firm is sponsoring the AHA ...
(Date:5/26/2020)... ... , ... After two months of tirelessly building an app to help people maintain social distance, ... that can take it and release it to the public. Why? Because if they don't, ... a tech startup founded in Richmond, VA by Stephen Dodge with the mission of creating ...
(Date:5/26/2020)... UPPER MARLBORO, Md. (PRWEB) , ... May 26, 2020 , ... ... by people of differing abilities to DC area hospitals, food pantries, group homes and ... our help, thank the healthcare workers on the front lines and bring a little ...
Breaking Medicine Technology:
(Date:5/27/2020)... PASS, Ore. (PRWEB) , ... ... ... 25 May 2020 , Guest: Dr. Gerald Pollack, University of Washington Professor ... Fourth Phase of Water: Beyond Solid, Liquid & Vapor ( ) ...
(Date:5/26/2020)... ... May 26, 2020 , ... Sex educator, activist, humanitarian, ... advocate Joan Price have just received the 2020 AASECT Audio Visual Award for jessica ... was the first of its kind to feature non-actors in its demonstrations and narratives ...
(Date:5/21/2020)... ... May 21, 2020 , ... In response to the Coronavirus pandemic, ... allows users to open swing-style doors without using their hands or fingertips. ... the door open using their forearm, wrist or elbow when entering or exiting a ...
(Date:5/21/2020)... ... May 21, 2020 , ... A Safe Haven Foundation (ASHF) has ... $5 million AbbVie COVID-19 Community Resilience Fund. The fund was created in March to ... frontline homeless workers in service to vulnerable populations in hard-hit communities. , “We ...
(Date:5/21/2020)... TAMPA, Fla. (PRWEB) , ... May 21, 2020 , ... ... redefined normal, there have been a lot of complications and adjustments, needless to say, ... to the highest level since the great depression it can be hard to escape ...
Breaking Medicine News(10 mins):